Hikma Starts Added-Value Push With Heparin Syringes
Heparin marks the start of Hikma’s pre-filled syringe portfolio in the US as the company looks to add value and differentiation to its injectables portfolio and pipeline, commercial and business development head Dan Motto told Generics Bulletin.
You may also be interested in...
London-listed Hikma has signed a second partnership agreement with Arecor, proposing to co-develop a 505(b)(2) hybrid injectable product for the US market.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.
Launching eight heparin vial presentations in the US is evidence of how injectables specialist Meitheal Pharmaceuticals intends to leverage the vertically-integrated production capacity of its Chinese parent group NKF.